Compare BridgeBio Pharma Inc (BBIO) vs Honest Company Inc (HNST) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

HNST trades at $5.23, down 4.21% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows mixed fundamentals with Q2 2026 EPS beating estimates at $0.04 versus $0.00926 expected, though revenue declined to $342M in 2026 with a net loss of $12M. Operating cash flow improved to $57M in 2026, and strategic exits are showing progress according to recent company updates.

The outlook remains cautious due to persistent net losses and margin pressure, offset by improving cash flow and recent earnings beats. Key risks include sustained profitability challenges and competitive pressures in personal care markets, while analyst sentiment is mixed with 30% buy ratings amid ongoing turnaround efforts.